CompletedPhase 4

Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

40 participantsStarted 2008-09

Plain-language summary

PG-analogues induce hyperemia as one of side effects in addition to IOP reduction. IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified. Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs. Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.

Who can participate

Age range20 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. normal healthy eye
✓. not applicable for IOP level
✓. not wearing contact lenses
✓. not applicable for the presence of the ocular surface diseases in case the treatment was not needed

Exclusion criteria

✕. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection
✕. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months
✕. the eyes with difficulty for the measurement of IOP with the applanation tonometer
✕. the subjects with the allergy for PG-analogues or benzalkonium chloride
✕. the subjects using the eyedrops excluding those in this study
✕. the subjects treated with oral carbonic anhydrase inhibitor
✕. the subject with Sjogren syndrome
✕. the subjects who can not drop periodically

What they're measuring

IOP reduction

Timeframe: 1 day

Trial details

NCT IDNCT02136589

SponsorTokyo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-12

View on ClinicalTrials.gov More Hyperemia trials